Business Context and Reporting Period
Company: PowerUp Acquisition Corp. (Note: Input metadata referenced "Aspire Biopharma," but the filing text identifies the registrant as PowerUp Acquisition Corp., a Cayman Islands exempted company and Special Purpose Acquisition Company (SPAC).)
Reporting Period: Quarterly period ended June 30, 2024.
Business Overview: The Company is a blank check company formed to effect a merger, share exchange, or similar business combination. As of June 30, 2024, the Company had not commenced any operations. The Company entered into a Merger Agreement with Visiox Pharmaceuticals, Inc. in December 2023. On July 19, 2024 (subsequent to the reporting period), the Company terminated this agreement because closing conditions were not satisfied by the June 30, 2024 deadline.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Net Loss (Income) | $(3,069,359) | $4,684,250 |
| Operating Expenses | $3,023,690 | $612,811 |
| Interest Income (Trust Account) | $404,765 | $5,297,061 |
| Total Assets | $6,867,584 | $19,982,392 |
| Trust Account Balance | $6,524,611 | $19,901,169 |
| Total Liabilities | $6,240,280 | $403,328 |
| Working Capital Deficit | $(5,897,306) | N/A (Positive Equity in 2023) |
| Cash and Cash Equivalents (Operating) | $0 | $125,201 |
Material Changes vs. Prior Period
- Significant Reduction in Trust Account: The Trust Account balance decreased from approximately $19.9 million to $6.5 million. This was primarily due to the redemption of 1,226,085 Class A ordinary shares in May 2024 (approx. $13.8 million) in connection with an extension of the business combination deadline.
- Shift from Profit to Loss: The Company reported a net loss of $3.07 million for the six months ended June 30, 2024, compared to net income of $4.68 million in the prior year period. The loss was driven by a sharp decline in interest income from the Trust Account and a significant increase in operating expenses.
- Increased Operating Expenses: Operating expenses rose to $3.02 million from $0.61 million year-over-year. This includes a $2.0 million expense related to subscription agreements associated with the terminated Merger Agreement.
- Accumulated Debt: Current liabilities increased significantly to $6.24 million, driven by a new "Subscription Agreement loan" of $4.93 million and "Loan and Transfer notes payable" of $0.43 million, compared to minimal liabilities in the prior period.
Outlook, Risks, and Management Commentary
- Termination of Merger: The Company terminated its Merger Agreement with Visiox Pharmaceuticals on July 19, 2024, as conditions were not met by the June 30, 2024 deadline. The Company intends to evaluate other targets but provides no assurance of success.
- Going Concern Doubt: Management has raised substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time (one year from issuance). The Company has $0 in its operating bank account and a working capital deficit of $5.9 million.
- Liquidity Needs: The Company may need to raise additional capital through loans or investments from the Sponsor, shareholders, or third parties to meet working capital needs. There is no assurance that financing will be available.
- Extension Deadline: Shareholders approved an extension to consummate a business combination by February 17, 2025. If no combination is completed by this date, the Company will liquidate and redeem public shares.
- Internal Control Weakness: The Company identified a material weakness in internal controls over financial reporting related to debt discount, amortization, and debt reporting.
Investor Verification Checklist
- Verify Company Identity: Confirm the filing is for PowerUp Acquisition Corp. (PWUP), not Aspire Biopharma, as the metadata may have been mislabeled.
- Assess Liquidity Risk: Review the $0 operating cash balance and $5.9 million working capital deficit to understand the immediate risk of insolvency without new financing.
- Review Debt Obligations: Examine the $4.93 million Subscription Agreement loan and $0.43 million Loan and Transfer notes payable, including their fair value adjustments and repayment terms.
- Monitor Extension Status: Track the February 17, 2025 deadline for a business combination and the likelihood of further extensions or liquidation.
- Check for New Targets: Monitor subsequent filings for any new merger agreements following the termination of the Visiox deal.